RBC Capital Remains a Hold on Becton Dickinson (BDX)

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Becton Dickinson, with a price target of $175.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Singh Chadha covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Insulet, and Boston Scientific. According to TipRanks, Singh Chadha has an average return of -1.1% and a 45.56% success rate on recommended stocks.

In addition to RBC Capital, Becton Dickinson also received a Hold from William Blair’s Andrew Brackmann in a report issued on July 2. However, on July 6, Citi reiterated a Buy rating on Becton Dickinson (NYSE: BDX).

Based on Becton Dickinson’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.71 billion and a GAAP net loss of $311 million. In comparison, last year the company earned a revenue of $5.27 billion and had a net profit of $308 million

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year. Last month, Thomas Polen, the COB, CEO & Pres of BDX sold 2,764.00 shares for a total of $404,511.40.